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Research Article

Design and development of Betaxolol hydrochloride in
situ hydrogel
Vinod S Panchal*, Jagadish K Saboji, Basavaraj K Nanjwade, Ramchandra N Chilkawar
Email: vndspanchal@gmail.com

Abstract
The present research work focusses on the improvement and assessment of ophthalmic medication delivery
system based on the idea of pH dependent in situ gelation for betaxolol hydrochloride (betaxolol HCl), an
anti-glaucoma operator, to conquer the issues of poor bioavailability and therapeutic response showed by
conventional formulations based a sol-to-gel change in the parkway up on instillation. Carbopol 940 was utilized
as pH sensitive gelling agent alongside HPMC as consistency upgrading specialist. Plans were assessed for
pH, clearness, sedate substance, gelling limit, and in-vitro drug discharge. The defined framework was clear in
appearance; pH of framework was inside scope of 5.1 – 5.6 and gave supported arrival of the medication over an
eight-hour time span. The created framework in this manner is a reasonable option to customary eye drops and
can be utilized as an in-situ gelling vehicle to improve ocular bioavailability and the reduction in the recurrence
of instillation along these lines bringing better patient compliance.
Key words: Betaxolol HCl, Carbopol 940, fluid gel-stage progress, in situ gelation, medication conveyance,
managed discharge, ophthalmic

Introduction
The one of a kind life structures, physiology, and
natural chemistry of an eye offer many challenges to
creating compelling ophthalmic medication delivery
system. Topical delivery into circular drive is, by a
long shot the most widely recognized course of visual
medication delivery. Despite the fact that different
ophthalmic plans exist in advertise, however are not
ready to give most elevated bioavailability identified
with controlled dose.1 Whenever an ophthalmic
medication is applied to the anterior segment of the
eye, only 5% really enters the cornea and achieves
concentration inside the eye. There are different
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variables that influence medication bioavailability,
such as, rapid solution drainage by gravity, instigated
lacrimation, squinting reflex, ordinary tear
turnover, superficial absorption of medication into
the conjunctiva and sclera and fast expulsion by the
peripheral blood stream, low corneal penetrability
(act as lipid barrier).2&3
β-adrenergic antagonist records for around
70% of all the solutions for glaucoma and are
valuable in the treatment of chronic open angle
glaucoma. These medications lessen intra ocular
pressure by contending with catecholamine for β
2-adrenoreceptor on the non-pigmented ciliary
epithelium and subsequently diminishing aqueous
humor creation. β-blockers have a few advantages
over cholinergic and adrenergic antagonist, as these
have little impact on pupil size and do not cause
mydriasis or responsive hyperaemia.4
The aim of this study was to prepare and evaluate pH
dependent in situ ophthalmic gel of an anti-glaucoma
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medication for sustained ocular delivery, which is
utilized for the treatment of glaucoma, to decrease
raised intraocular pressure (IOP), to show signs of
improvement persistent consistence by expanding
living arrangement time and bioavailability.
Betaxolol
hydrochloride or betaxolol HCl
(2-propanol,
1-4-2
(cyclopropylmethoxy)
ethylphenoxy-3
(1-methylethyl)
aminohydrochloride) was utilized as model medication.

Materials and methods
Materials
Betaxolol HCl was benevolently gifted from Hikal
Labs, Bangalore. Carbopol 940 and HPMC were
bought from HiMedia Labs Pvt Ltd Mumbai.
Benzalkonium chloride was bought from Ozone
chemicals, Mumbai. All other reagents and solvents
utilized were of analytical grade. Cellophane
membrane and distilled water were alternate
materials utilized.
Instruments used
UV-spectrophotometer (Shimadzu), Brookfield DV
Rheometer (Brookfield Engineering Laboratories),
Magnetic stirrer, Autoclave were the instruments
utilized for this investigation.
Method
Standard calibration curve
Standard medication solution of betaxolol HCL
was set up by dissolving 100 mg of unadulterated
betaxolol hydrochloride in a little measure of
Simulated Tear Fluid in 100 ml volumetric flask
and later the volume was balanced with Simulated
Tear Fluid solvent. The resultant solution gives
the concentration of 1mg/ml i.e. 1000µg/ml. From
above stock solution 10 ml solution was taken and
later diluted up to 100 ml with a similar solvent in
a volumetric flask. The concentration of this stock
was 100µg/ml. From this stock solution 02, 04, 06,
08, 10, 12, 14, 16, 18, 20, 30, 40, 50, 60, 70, 80, 90, and
100 ml solution pipette volume was made with 100
ml utilizing STF as a solvent to get centralizations
of 02, 04, 06, 08, 10, 12, 14, 16, 18, 20, 30, 40, 50,
60, 70, 80, 90, and 100µg/ml individually. The
absorbance was measured at 224 nm (lambda max
of betaxolol HCl). The standard calibration curve

was obtained from information of concentration v/s
absorbance.5
pH dependent in situ hydrogel
The buffer salts were dissolved in 75ml of distilled
water, HPMC was added and permitted to hydrate,
Carbopol was sprinkled over this solution and
permitted to hydrate overnight. The solution was
mixed with an overhead stirrer, betaxolol HCl was
dissolved in a little amount of water, benzalkonium
chloride was added to this solution, and the
medication solution was then added to make up the
volume to 100 ml. This solution was sifted through
0.2 mm filter paper.6 (Table 1)
Table 1: Formulation of pH triggered in situ gel of Betaxolol HCl
Sl
No
1

Ingredients
Betaxolol
hydrochloride

F2

F3

F4

F5

0.2

0.2

0.2

0.2

0.2

2

Carbopol 940

0.2

0.3

0.4

0.5

0.6

3

HPMC

1.5

1.5

1.5

1.5

1.5

4

Citric acid IP

0.407

0.407

0.407

0.407

0.407

1.125

1.125

1.125

1.125

1.125

0.02

0.02

0.02

0.02

0.02

100ml

100ml

100ml

5
6
7

Disodium
hydrogen
phosphate IP
Benzalkonium
chloride
Purified water

100ml 100ml

Assessment parameters
A. Appearance
B. pH
C. In vitro gelation studies and viscosity
D. Rheological studies
E. Drug content
F. In vitro drug release
G. Sterility
Appearance
Clarity of formulation is the most vital parameter,
highlighting an ophthalmic preparation. Every
created formulation was assessed for clarity by visual
inspection against a highly contrasting background
for the presence of any particulate matter, if
present.7
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pH determination
The two regions of basic significance are the impact
of pH on the solubility and stability of ophthalmic
preparation. The pH of ophthalmic dosage forms
should be such that the preparation should be steady
at that pH and in the meantime, there would be no
irritation to the patient upon administration of the
formulation. Ophthalmic dosage forms should have a
pH range of 5 – 7.4. The created formulations were
assessed for pH by utilizing equiptronic digital pH
meter.7
In vitro gelation study
All the prepared ophthalmic formulations were
assessed for gelling limit so as to distinguish the
pieces appropriate for use as in situ gelling system.
The gelling limit of formulation was determined by
putting a drop of the system in a vial containing
2 ml of simulated tear fluid freshly prepared and
equilibrated at 37o C and visually surveying the
gel development and taking note of the ideal
opportunity for gelation and the time taken for
the gel dissolved. The composition of simulated
or artificial tear fluid utilized was sodium chloride
0.670g, sodium bicarbonate 0.200g, calcium chloride
0.008g and purified water qs 100 ml.8
Rheological studies
Viscosity of ophthalmic formulation is an essential
factor in deciding residence time of medication in the
eye. The prepared sol was permitted to gel in STF
and later viscosity was measured. Viscosity of the
sample was measured at various angular velocities.
A typical run comprised changing angular velocity
from 10 to 100 rpm with measure up to weight for
every rpm. The average of two readings was utilized
to ascertain the viscosity.9
Drug content
The drug content of in situ gel was determined
by taking sample (5ml) of in situ gel in 10 ml of
volumetric cup and diluted with STF of pH 7.4 to
get the concentration of 10 µg/ml. At that point,
the absorbance was measured at 224nm utilizing
UV-spectrophotometer to compute the level of drug
content.10
8
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In vitro release studies
The Franz-diffusion cell was utilized for studying in
vitro release of the in situ gel. A cellulose acetate
membrane (membrane with 25mm diameter) was
adjusted to the terminal bit of the cylindrical donor
compartment. 1ml in situ gel containing drug,
adequate for establishing sink states of the measure
was put into the donor compartment. The receptor
compartment containing 16 ml of simulated tear
fluid of pH 7.4 was kept up at 37o C under mild
agitation utilizing magnetic stirrer. At particular
time intervals, aliquots of 1ml were withdrawn
and quickly replaced with a similar volume of crisp
STF. Measuring the absorbance at 224 nm utilizing
UV spectrophotometer11 assessed the measure of
medication released.
Sterility test
Sterility testing was performed for the aerobic and
anaerobic microbes and fungi by utilizing liquid
thioglycolate medium and soybean-casein medium
respectively according to the Indian Pharmacopoeia.
Formulation was taken in to laminar air flow and
passed through a membrane filter of 0.45µm with
the assistance of vacuum pump. After filtration,
the filter paper was expelled from funnel and cut
into two parts. One half was dropped in bacterial
media (liquid thioglycolate) and the other was split
dropped in fungal media (soya bean casein digest).
The two media were kept for incubation at 37o C for
seven days and observed for any microbial growth.12
Comparative evaluation of marketed product
with prepared in situ gels
In vitro release studies of marketing formulation
was completed utilizing bi-chambered donor receiver
compartment model (Franz diffusion cell) utilizing
a cellophane film soaked overnight the receptor
medium (recreated tear fluid pH 7.4) The diffusion
medium was 16 ml of simulated tear fluid mixed at
50 rpm at 37o C ± 0.5o C. One end of diffusion cell
was secured by a cellophane membrane and 1 ml of
prepared formulation was spread on the cellophane
film and membrane was put in such a way, so that
it simply touches the diffusion medium simulated
tear fluid present in receptor compartment. The
medication tests were withdrawn back at once
interim of one hour for the time of eight hours
from diffusion medium and investigated by UV
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spectrophotometer at 224 nm utilizing simulated
tear liquid as blank.
Results and discussion
Assessment of appearance, clarity, pH, and drug
All the prepared in situ gelling systems were
evaluated for preliminary steps such as visual
appearance, clarity, pH, and drug content. These pHdependent formulations were transparent and clear.
The pH of pH-dependent formulation was found to
be in the range of 5.1 – 5.6. As concentration of
Carbopol increases, pH of solution decreases. The
drug content was found to be in the acceptable range
of all formulations. Drug content of pH dependent
in situ gel was ranging from 90.12 – 96.75%.
Formulation F3 showed a drug content of 96.75%.
This indicates that drug is uniformly distributed
throughout the system. (Table 2)
Table 2: Preliminary evaluation of pH dependent in situ gelling
system of visual appearance, clarity, pH, and drug content
Formulation
code

Visual
appearance

Clarity

pH

Drug
content

F1

Transparent

Clear

5.64

90.12

F2

Transparent

Clear

5.53

94.31

F3

Transparent

Clear

5.37

96.75

F4

Transparent

Clear

5.23

95.84

F5

Transparent

Clear

5.12

92.61

In vitro gelation
Prepared in situ gelling systems were evaluated for
the in vitro gelation capacity. Formulations F3, F4,
F5 gelled instantaneously (less than a minute) on
contact with STF. F1, F2 formulation gelled after a
few minutes. By visual inspection, the formulations
formed a translucent matrix in addition to the STF.
(Table 3)
Table 3: Evaluation of gelling capacity
Formulation code

Gelling capacity

F1

+

F2

++

F3

++

F4

+++

F5

+++

– No gelation
+ Gels after a few minutes and remains for a few hours
++ Gels immediately and remains for a few hours
+++ Shows gelation immediately and remains for extended
period

Rheological studies
For the development of optimum in situ gelling
system, two major factors viscosity and gelling
capacity should be taken into consideration, since the
ocular shear rate is very high ranging from 0.03S1
during blinking. During blinking, viscoelastic
fluid with a viscosity is high under low shear rate
condition and low under high shear rate condition,
which is called pseudo plastic fluid, is often preferred,
so dynamic viscosity of formulations were measured
as the change of shear rate before and after gelation.
Table 4 and 5 shows viscosity values obtained
for all pH dependent in situ formulations using
Brookfield LVDL-I PRIME. The viscosity was
directly dependent on the polymeric content of
the formulation. The viscosities of formulations
were in following range F5> F4> F3> F2> F1.
As a proportion of gelling agent Carbopol 940 and
viscosifying agent HPMC increased, there is an
increase in consistency of in situ gel. This is due to
the characteristic of Carbopol 940 to convert into
more rigid structure due to change in pH when comes
in contact with pH 7.4. The addition of HPMC
potentiates this rigid structural arrangement of
Carbopol 940 and ultimately resulting in increased
consistency.
Sterility testing
Formulated pH dependent betaxolol HCl in situ
gelling systems were evaluated for sterility. There
was no appearance of turbidity and hence no evidence
of microbial growth when all the formulations were
incubated for seven days at 30o C – 35o C in case
of fluid thioglycolate medium and at 20o C – 25o
C in case of soybean-casein digest medium. The
preparations being examined therefore passed the
test for sterility.
In vitro diffusion studies
The in vitro diffusion of betaxolol hydrochloride
from the prepared formulation was studied through
a cellophane membrane using diffusion cell using
STF of pH 7.4 as diffusion medium. The diffusion
studies of prepared in situ gelling systems carried
up to 8 hours. In vitro diffusion studies of marketing
eye drop (IOBET) was done through a cellophane
membrane using diffusion cell STF of pH 7.4 as
diffusion medium and the release-marketed product
was up to three hours.
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Table 4: Viscosity of pH dependent in situ gel formulation before and after gelation
Viscosity of pH dependent Betaxolol HCl in situ gel (cps)
F1

Angular
velocity

Before

F2
After

Before

gelation gelation gelation

(rpm)

F3

F4

F5

After

Before

After

Before

After

Before

After

gelation

gelation

gelation

gelation

gelation

gelation

gelation

10

180

16110

239

22755

659

33490

1680

37940

2280

40110

20

150

15590

210

26510

539

31890

1410

35140

1710

38250

30

140

12210

180

23810

479

29240

1109

28160

1380

36510

50

132

10970

156

18740

365

27620

903

26220

1192

31490

60

130

9960

150

16550

395

22210

889

24730

1020

28420

100

120

8750

144

12470

323

18740

547

21680

839

26470

Table 5: In vitro diffusion data of pH dependent in situ gelling system and marketing eye drop
TIME

F1

F2

F3

F4

F5

Marketed eye drop

30

-

-

-

-

-

24.34

60

31.89

23.65

20.46

15.68

11.16

45.18

120

47.12

32.14

30.49

29.32

27.41

75.48

180

53.33

39.2

36.39

38.94

34.69

96.61

240

43.45

43.45

40.05

42.6

45.42

-

300

72.83

55.3

46.27

48.24

53.33

-

360

81.86

66.35

52.48

55.88

59.28

-

420

90.31

75.65

62.37

65.18

62.37

-

480

94.03

89.76

74.8

69.7

67.47

-

pH dependent Betaxolol HCl in situ gelling
system
In vitro diffusion studies were carried out for F1 – F5
pH dependent in situ gel formulations using STF as
a diffusion medium in the Franz - diffusion cell. The
data of these release studies are presented in table 8.

It was found that drug release was 94.03%, 89.76%,
74.80%, 69.70%, and 67.47% for the formulations
F1 – F5 respectively after eight hours. These values
indicate F3 showed a better optimum sustaining
effect amongst all formulations. This may be due to
the optimum concentration of Carbopol 940 along

Fig 1: Viscosity of pH dependent in situ gel formulation before gelation
10
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with HPMC in F3. Figure 4, shows the plot of In
vitro diffusion studies for all the formulations along
with a comparative study of marketing eye drop
drug release profile.

The developed formulation is a viable alternative
dosage form to conventional eye drops by virtue of
its ability to enhanced and longer therapeutic effect
through its longer pre-corneal residence time and
ability to sustain drug release.
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Fig 2: Viscosity of pH dependent in situ gel formulation after
gelation
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Fig 3: In vitro diffusion profile of marketed eye drop (IOBET)

Fig 4: Shows the plot of in vitro diffusion studies for all the
formulations along with a comparative study of marketed eye
drop drug release profile

Conclusion
Betaxolol HCl, used in treatment of glaucoma was
successfully formulated as pH dependent in situ
gel forming ophthalmic solution using Carbopol
as gelling agent and HPMC as a viscosityenhancing agent. The formulation was liquid in
non-physiological conditions (pH 4.0 and 25° C)
and transformed to the gel form in physiological
conditions (pH 7.4 and 37° C). Formulation shows
sustained drug release over a period of eight hours.
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